Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS

Illustration of red boulder/ball rolling down toward businessman

Job Trends

Early-Career Professionals Face Steep Climb in Tight Market

Some companies’ preferences for people who already have industry experience and the tough job market are among the hurdles those just starting out in biopharma must navigate, two recruitment experts told BioSpace.

June 11, 2025

5 min read

Angela Gabriel

Contemporary art collage. Human hand holding megaphones and spreading fake news. Concept of information, creativity, social issues, rumors. Copy space for ad

Opinion

How Poor Communication Can Sink Drugs’ Prospects

Despite substantial investments in groundbreaking treatments, companies struggle to communicate value early and to the right audience. Here’s how they can do better.

June 11, 2025

4 min read

Amit Patel

Holds tickets in hand, isolated on white background. Vector flat. stock illustration

Deals

Biopharma Right of First Negotiation Not a Golden Ticket to M&A, Jefferies Finds

Looking at licensing deals struck in the past 10 years, Jefferies found that many Big Pharmas do not ultimately follow through with M&A after earning a right of first negotiation. Sanofi, on the other hand, almost always does, as it did with Vigil recently.

June 11, 2025

6 min read

Annalee Armstrong

Substitution of DNA with bare hands and an ordinary screwdriver.

Business

As Gene Therapy Endures ‘Cold Winter,’ FDA Leaders Promise Support

Gene therapies have ridden investor mania to huge valuations but commercialization challenges have pushed market caps to the floor. At a roundtable last week, FDA leaders promised faster approvals and broad support to the industry.

June 11, 2025

6 min read

Dan Samorodnitsky

Special edition

Deep Dive: Top Paid Pharma Execs—and Those Who Would Get the Most to Leave

BioSpace did a deep dive into executive pay, examining the highest compensation packages, pay ratios and golden parachutes—what a CEO would get paid to leave.

June 10, 2025

2 min read

Annalee Armstrong

Chalk drawing arrow turn or break through road block traffic pylon on dark blackboard using as obstacle, solution for business problem or break through to success concept.

Infectious disease

Gilead’s HIV Combo on Hold, With No Impact on FDA’s Pending Lenacapavir Decision

Gilead underscored its faith in the combo therapy and pledged to work with regulators to resolve the hold, which has paused five clinical trials. Gilead also stressed that the hold does not impact any other assets in its HIV pipeline.

June 10, 2025

3 min read

Annalee Armstrong

Vaccines

‘More Critical’ Vaccine Advisors Expected Following Kennedy’s ACIP Ouster

Robert F. Kennedy Jr.’s removal of all remaining members of the CDC’s Advisory Committee on Immunization Practices raises questions about the upcoming meeting later this month. Analysts fear the committee could be more sympathetic to the HHS Secretary’s anti-vax viewpoints.

June 10, 2025

3 min read

Heather McKenzie

Illustration of employer’s hand holding employee who was laid off to drop him out of office

Layoffs

Recursion Downsizes by 20% To Boost Cash Position

As of March 31, Recursion Pharmaceuticals had a cash position of $509 million. Following Tuesday’s layoffs, the biotech expects its runway to last into the fourth quarter of 2027.

June 10, 2025

2 min read

Tristan Manalac